Gilead Sciences, Inc. GILD today announced interim results
from a single-arm, open-label Phase 2 study (Study 101-09) evaluating
idelalisib (formerly GS-1101), an investigational, targeted, oral
inhibitor of PI3K delta, for the treatment of patients with indolent
non-Hodgkin's lymphoma (iNHL) that is refractory (non-responsive) to
rituximab and to alkylating-agent-containing chemotherapy. Previously,
this has been a largely unstudied population for which there is
significant unmet medical need for effective therapy. In the study,
single-agent treatment with idelalisib achieved an overall response rate
of 53.6 percent, with a median duration of response at this interim
analysis of 11.9 months. Detailed study results will be presented this
Thursday during an oral session at the 12th International
Conference on Malignant
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in